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Abstract c-Abl tyrosine kinase, an essential protein of the cell
cycle signalling pathways, is implicated in the regulation of RNA
polymerase II activity, apoptosis and DNA repair. Its DNA
binding activity is important for its biological functions.
However, the molecular basis of c-Abl interaction with DNA
remains largely unclear. We delimited the human c-Abl DNA
binding domain and identified its preferred binding site, 5P-
AA/CAACAAA/C. The central AAC motif is highly conserved
and constitutes the major core element in the binding sites.
EMSAs and footprinting experiments were performed to explore
how the c-Abl fusion protein recognizes specific sequences in
DNA.
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1. Introduction
The p145cÿAbl protein is a member of the c-Src non-recep-
tor tyrosine kinase family. In its N-terminal part, c-Abl con-
tains several domains common to c-Src tyrosine kinase but in
its C-terminal part, it possesses speci¢c functional regions in-
cluding the nuclear localization signal [1,2], an actin binding
site [3] and a DNA binding domain [4]. Mutations within the
last exon encoding the large C-terminal domain are su⁄cient
to activate the transforming potential of c-Abl [5].
Human and mouse c-Abl proteins contain two proline-rich
regions within the central portion of their last exon. The DNA
binding domain whose activity is regulated during the cell
cycle by the cdc2 kinase, contains one of the two proline-
rich regions [6]. At early stages of mitosis, cdc2 kinase phos-
phorylates c-Abl on serine and threonine residues. Hyper-
phosphorylation of the c-Abl DNA binding domain on Ser-
852 and Ser-883 residues results in an inhibition of the DNA
binding activity of c-Abl during mitosis [4]. In addition, the c-
Abl tyrosine kinase can negatively regulate cell growth via a
p53-dependent pathway [7,8]. c-Abl tyrosine kinase activity is
also regulated during G2, M and G1 phases of the cell cycle
by interaction with the retinoblastoma protein RB in order to
abolish the c-Abl tyrosine kinase activity [9,10].
The C-terminal repeat domain (CTD) of the RNA polymer-
ase II large subunit has been identi¢ed as a nuclear substrate
for c-Abl tyrosine kinase which phosphorylates tyrosine resi-
dues present in the 52 amino acid repeats [11]. The tyrosine
phosphorylation is believed to participate in the transition
from initiation to elongation phases of the basal transcription
complex, as do serine and threonine phosphorylations on the
CTD [12].
Although it has been known for some time that c-Abl binds
to DNA, the type of sequence targeted by the protein is still a
matter of debate. Dikstein et al. [13,14] have shown that c-Abl
binds to the palindromic EP sequence of the hepatitis B virus
enhancer but others have failed to ¢nd this interaction [15,16].
The activation of c-myc transcription by c-Abl [17] apparently
depends neither on an EP-like element in the c-myc promoter
nor on the DNA binding domain of c-Abl [15]. Therefore, the
nature of c-Abl binding sites on DNA remains an area of
ongoing controversy and it is the issue we addressed here.
2. Materials and methods
2.1. Binding of proteins mutants to DNA-cellulose
The DNA fragment [BglII 1233^BglII 3440] of the pSP65BCR-ABL
plasmid encoding the C-terminal domain of human Abl protein was
cloned into the pcDNA3 plasmid (InVitrogen). Several restriction
sites in the c-Abl cDNA sequence were used for generating deletion
mutants (Fig. 1). In vitro transcription and translation were per-
formed with 1 Wg of the various plasmids in TNT-reticulocyte lysates
(Promega) and labelled using [35S]methionine. The labelled products
were incubated for 1 h at 4‡C with 40 Wl of DNA-cellulose (Pharma-
cia) pre-equilibrated in binding bu¡er (20 mM Tris-HCl pH7.4, 40
mM NaCl, 0.2% NP40, 1 mM EDTA, 1% aprotinin). After two
washes with the same bu¡er, the protein-DNA complex was eluted
with increased saline bu¡er (binding bu¡er supplemented with 100
mM, 300 mM, 500 mM and 1 M NaCl). Each fraction was resolved
on 15% SDS-PAGE and quanti¢ed using a PhosphorImager. The
S1A2, S2A2 and S1A1 proteins were obtained from the pAlter-
EX1-derived vectors (Promega).
2.2. Determination of predicted secondary structure
The potential secondary structure of the NX-HIS fusion peptide
was determined using the GSM [18], Garnier [19], Gibrat [20], Levin
[21,22], DPM and SOPMA [23] computer programs.
2.3. Expression and puri¢cation of the human c-Abl DNA binding
domain in bacteria
The [NcoI 2373^XmaIII 2912] sequence was fused at the 3P end to a
(His)7 coding oligonucleotide, in order to purify the protein on Ni
beads, and cloned in the pTRC-99A vector (Pharmacia) or the pAlter-
EX1 plasmid. The NcoI site at position 2373 was created by muta-
genesis. The pTRC-99A-NX-HIS construct was used to obtain a bac-
terially expressed NX-HIS protein. The NcoI-MluI DNA fragment
was subcloned into pGEX-2T vector (Pharmacia). The GST-NX-
HIS fusion protein was expressed in Escherichia coli strain JM109
by induction with IPTG, puri¢ed using Ni columns under denaturing
conditions and then refolded to a native structure by gradual dialysis
against the EMSA incubation bu¡er (50 mM HEPES pH 7.9, 100
mM KCl, 5 mM EDTA, 1 mM PMSF, 20% glycerol). The protein
preparation was analyzed by SDS-PAGE. Gels were stained with
Coomassie blue or used for immunoblot in standard methods using
a polyclonal anti-GST antibody. The capacity of the proteins to bind
to DNA was veri¢ed via an interaction with DNA-cellulose, prior to
be used in the cyclic ampli¢cation of sequence targeting (CASTing)
experiments.
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2.4. Selection of binding sites by CASTing [24]
5 Wg of the R62 oligonucleotide (CAGGTCAGTTCAGCG-
GATCCTGTCG(N)12GAGGCGAATTCAGTGCAACTGCAGC)
was added to 5 Wg of the reverse primer, heated to 95‡C and cooled
slowly to room temperature prior to adding the dNTPs and the Kle-
now enzyme (10 units) and then incubated for 30 min at 37‡C. The
double-stranded 62-mer oligonucleotides were mixed with 50 ng of the
puri¢ed GST-NX-HIS protein in 100 Wl binding bu¡er (20 mM
HEPES, pH 7.9; 100 mM KCl, 20% glycerol, 10 mg/ml BSA, 1 mM
PMSF) in the presence of aprotinin (1 Wg/ml) and 0.5 Wg of poly-
(dI-dC)W(dI-dC) and then incubated for 30 min at 4‡C. 25 Wl of pre-
equilibrated Ni bonds was added for 15 min at 4‡C before washing
5^10 times with the same bu¡er. The washed pellet was resuspended
in 50 Wl of PCR bu¡er (Appligene), heated for 5 min at 95‡C and the
supernatant was subjected to 10 cycles of PCR (1 min at 94‡C, 1 min
at 65‡C and 2 min at 72‡C) in a ¢nal volume of 100 Wl PCR bu¡er
containing 15 pM of the reverse and forward primers. An aliquot was
analyzed on a 3% agarose gel. When no ampligene was visualized,
10 additional PCR cycles were performed. Nine rounds of binding
and ampli¢cation were undertaken using reduced protein concentra-
tions and increasing KCl (up to 300 mM) and poly(dI-dC)W(dI-dC) (up
to 5 Wg per reaction). Subsequently, the selected fragments were
cloned in the pBSIISK vector and sequenced.
2.5. Electromobility shift assays
The cloned fragments isolated by CASTing were 3P end-labelled
with [K-32P]dCTP (3000 Ci/mM, Amersham, UK) using the Klenow
enzyme. The labelled probes (10 000 cpm, 5 ng) were incubated with
GST-NX-HIS in EMSA binding bu¡er (50 mM HEPES pH 7.9; 100
mM KCl; 1 mM DTT; 5 mM MgCl2 ; 0.1 mM EDTA; 20% glycerol;
500^1000-fold poly(dI-dC)W(dI-dC); 1 mM PMSF). Electrophoresis
was carried out on a 6% polyacrylamide gel in a 0.7UTAE bu¡er
(4.7 mM Tris-HCl; 2.3 mM Na-acetate; 0.7 mM EDTA; pH 7.9) at
100 V.
2.6. DNase I experiments
DNase I footprinting was performed as described [25]. The XbaI-
XhoI-labelled fragment of pBSIISK-05 was incubated with the puri¢ed
protein and subjected to the nicking activity of DNase I. DNA cleav-
age products were resolved by electrophoresis on a 8% polyacrylamide
gel containing 8 M urea. Electrophoresis was performed at 85 W in
TBE bu¡er (100 mM Tris-HCl; 100 mM boric acid; 2 mM EDTA;
pH 8.3).
3. Results
In previous studies using the mouse c-Abl protein [4], the
DNA binding domain was localized in the C-terminal region,
between the kinase domain and the actin binding site (Fig. 1).
To delimit the position of the DNA binding domain in the
human protein, we performed multiple deletion mutants (see
Fig. 1). The so-called BB and S1A2 fragments correspond to
the large C-terminal domain of c-Abl. The deletion mutants
were transcribed and translated in reticulocyte lysates using
T7 RNA-polymerase and the labelled proteins were tested for
their DNA-cellulose a⁄nity (Fig. 1). The BglII-SmaI and
ApaI-BglII segments located on the 5P and 3P sides of the
largest BB fragment, respectively, are not absolutely required
for the interaction with DNA. Indeed, deletion of either the 3P
segment (mutant BBvApa) and the 5P segment (mutant S1A2)
has little or no e¡ect on the interaction of the protein with
DNA-cellulose. The simultaneous deletion of those two seg-
ments (mutant S1A1) con¢rms that the DNA binding domain
is located between the SmaI 1469 and the ApaI 2752 sites. The
protein mutant BBvSma with a large deletion between the
two SmaI sites shows a slightly reduced a⁄nity for DNA
whereas deletion between the two PstI sites (mutant
BBvSma-vPst) almost completely abolishes the DNA binding
capacity of the protein. The analysis of the various deletion
mutants suggests that the DNA binding domain of human c-
Abl is mainly located between the SmaI 2564 and the ApaI
2752 sites. However, the sequences on the 5P side of the SmaI
2564 site may also be important for the interaction with DNA
(compare mutants S1A2 and S2A2). For this reason and to
make sure that the fusion protein will interact with DNA, we
cloned a fragment NcoI (2373)^XmaIII (2912) which is slightly
longer than the required SmaI (2564)^ApaI (2752) segment.
The NX-HIS protein, produced in reticulocyte lysate, and the
protein GST-NX-HIS produced in bacteria show the same
DNA binding capacity as the full length c-Abl C-terminal
domain (BB) (Fig. 1), whereas the GST protein alone failed
to bind to DNA-cellulose (unpublished control). The protein
GST-NX-HIS which can be produced in large quantity in
bacteria was used for the di¡erent experiments described
here below.
Five computer programs were employed to predict the sec-
ondary structure of the DNA binding domain of c-Abl. The
agreement between the di¡erent methods is satisfactory. They
all predicted roughly the same structure. A consensus struc-
ture was deduced from the complementary analysis. As indi-
cated in Fig. 2, the DNA binding domain of c-Abl would be
composed of three K-helices and three potential L-sheets sep-
arated by coiled regions of variable lengths.
CASTing experiments were undertaken to identify the se-
quence preferentially recognized by the minimal DNA binding
domain of the human c-Abl protein. The GST-NX-HIS fusion
protein was incubated with 62-mers containing 12 random
base pairs, the bound sequences were subjected to nine rounds
of selection-ampli¢cation and the last ampligenes were cloned.
Among the 47 selected sequences (Fig. 3), 41 showed a high
homology and were used to display out the consensus binding
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Fig. 1. Binding of c-Abl deletion mutants to DNA-cellulose. The de-
letion and fusion proteins were prepared with the indicated restric-
tion enzymes. The relative a⁄nity of the deletion mutants is given
with respect to that of the BB protein used as a control (eluted
with 300 mM NaCl). Symbols +++ and ++ indicate that the DNA
binding capacity is equivalent and slightly reduced compared to that
of the BB protein, respectively. The symbol þ denotes weak bind-
ing capacity. The double deletion mutant BBvSma-vPst binds to
the DNA-cellulose only at low stringency (100 mM NaCl).
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site AA/CAACAAA/C. It is remarkable to observe that all
these sequences contain an AAC motif. Many sequences, in-
cluding the six not used for the determination of the consen-
sus sequence (bottom of Fig. 3), correspond to AT-rich
stretches. The size of the selected sequences varies from 11
to 30 base pairs and 15 of the 41 selected sequences, as well
as the non-selected but AT-rich clone 25, encompass more
than 12 base pairs.
In order to test the ability of GST-NX-HIS fusion protein
to preferentially bind to one or another selected sequences, a
few clones (01, 02, 03, 05, 10, 17 and the control SK that does
not contain any potential binding site) were employed in EM-
SAs using radiolabelled XbaI-XhoI fragments (73 or 78 bp)
spanning the cloned selected sequences. Protein-DNA com-
plexes can be identi¢ed with clones 01, 02, 03 and 05 and to
a much lower extent with clone 10 but not with clone 17 and
the control probe SK that lacks the target site but does con-
tain the same £anking sequences (Fig. 4). The XbaI-XhoI frag-
ment of clone 17 which does not contain the determined con-
sensus binding site fails to bind to the protein (Fig. 4, lane
12). The binding a⁄nity of GST-NX-HIS for the XbaI-XhoI
probes varies signi¢cantly. The ranking order is
05s 01s 02s 03s 10s 17. Probe 05, which bears three jux-
taposed AAC triplets, exhibits the highest a⁄nity for the pro-
tein. We also used a shorter fragment using BamHI and
EcoRI restriction enzymes (32 or 37 bp) as probe in EMSAs.
Interestingly, the GST-NX-HIS fusion protein binds very
weakly to the BamHI-EcoRI 05 probe whereas it binds tightly
to the longer XbaI-XhoI probe.
The relatively weak a⁄nity of the protein for DNA can be
attributed to the fact that only a limited fraction of the pro-
tein is correctly refolded. The e⁄ciency of the folding process
is unknown and it is plausible that the preparation contains
both folded and partially folded (i.e. inactive) conformers.
The exact position of the protein binding site within probe
05, which presents the highest binding ability for GST-NX-
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Fig. 2. Potential secondary structure of the NX-HIS fusion peptide. The computer programs GSM, Garnier, Gibrat, Levin, DPM, and SOPMA
were used to determine the position of the K-helices, L-sheets or coiled structures within the DNA binding domain of c-Abl (fragment corre-
sponding to the NX protein). The consensus sequence was derived from the complementary computer analyses. H, E, C and T represent K-he-
lix, L-sheet, coil and turn conformations, respectively.
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HIS, was located by means of DNase I footprinting. As
shown in Fig. 5, the sequence protected from cleavage by
the nuclease coincides with the sequence identi¢ed in the
CASTing experiments. There is no binding to the vector se-
quences or to the primers and cloning site sequences. There-
fore, the EMSA and footprinting data concur that the protein
binds selectively to 5P-AAC (GTT)-containing sequences.
4. Discussion
We have shown that the DNA binding domain of c-Abl can
recognize a speci¢c consensus sequence in DNA. The se-
quence selectively targeted by c-Abl is reminiscent of the se-
quence bound by HMG-like proteins such as LEF-1 and SRY
which bind preferentially to 5P-AACAAAG and 5P-
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Fig. 3. The oligonucleotides 01^40 were sequenced after nine rounds of selection-ampli¢cation for c-Abl DNA binding ability. The upper se-
quences are aligned to show the sequence homology and were used to determine the consensus shown in bold letters.
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A/TAACAAA/T, respectively [25^27]. The DNA binding do-
main of human p145cÿAbl, which we have located from a
series of deletion mutants, appears to be homologous to
that previously identi¢ed for the mouse p150cÿAbl protein
[4]. This domain does not share any homology with other
known DNA binding domains such as basic leucine zipper
or zinc ¢nger motifs, but presents a high proline content
(the NX peptide contains 15% prolines). Using ¢ve computer
programs, the L1-K1-L2-K2-K3-L3 predictive secondary struc-
ture was determined (Fig. 2). However, the potential K-helices
are much shorter than those usually found in the DNA bind-
ing domain of proteins with a helix-loop-helix motif. There-
fore, c-Abl apparently belongs to a distinct class of DNA
binding proteins. In a recent study, Miao and Wang [16] re-
ported that the mouse c-Abl DNA binding domain contains
three HMG-related domains. Our own analysis with the hu-
man protein does not agree with this view. Not only do the
three domains described by Miao and Wang di¡er signi¢-
cantly from one another but in addition they are devoid of
tryptophan, tyrosine and threonine residues that are almost
always found in the DNA binding domain of HMG and the
related HMG-like proteins [29].
The analysis of the sequence speci¢city of c-Abl shows un-
ambiguously that the human protein exhibits a high prefer-
ence for sequences containing an AAC motif. Here again, the
results are not totally consistent with those reported with the
mouse protein. Miao and Wang indicated that p150cÿAbl in-
teracts preferentially with AT-rich tracts as do HMG proteins
[28], but that the mouse p150cÿAbl protein does not recognize
any particular sequences. In our hands, the human protein
binds to certain AT-rich sequences but largely prefers AAC-
containing sequences. All the binding data concur that AAC-
based sequences are much more preferred than purely AT-rich
sequences. In this respect, it is worth noting that the human c-
Abl protein was previously shown to bind to the EP palin-
dromic element of the HBV enhancer which corresponds to
the sequence CGTTGCtcgGCAACG [13]. Interestingly, we
note that this EP element is not AT-rich but contains two
AAC motifs. The highly conserved AAC motif is likely im-
portant for the protein-DNA recognition process to occur but
it is surely not su⁄cient. The nature of the £anking nucleo-
tides of the consensus sequence is important as well.
The observations that (i) the fusion protein binds more
tightly to 73-mer sequences than to 32-mer containing the
same binding core and (ii) the sequences selected by CASTing
are frequently longer than the 12 bp randomized sequence
suggest that the protein recognizes a central core as well as
a particular DNA structure. The £anking sequences likely
contribute to a reinforcement of the a⁄nity of the protein
for its target site. We also performed EMSA using GST-
NX-HIS and the 05-selected sequence included in DNA frag-
ments of several lengths and found that the binding a⁄nity
increased up to a size of 66 bp (data not shown). The same
binding ability was observed with the c-Myb minimal DNA
binding domain which needs a 3P extension of more than 10
bp to allow binding to the MRE (Myb responsive element).
This extension of one turn of the helix is important for sta-
bilizing the protein-DNA complex and increasing its half-life
[30].
c-Abl has been implicated in DNA recombination and re-
pair [31] and very recently in the regulation of DNA damage-
induced apoptosis [32]. So far, it has not been possible to
establish a direct connection between these biological e¡ects
and the particular DNA binding capacity of the protein.
However, the interaction of c-Abl with its DNA consensus
binding site may permit the correct positioning of c-Abl ty-
rosine kinase within the transcription complex so as to facil-
FEBS 19936 11-3-98
Fig. 4. EMSA showing the binding of the DNA binding domain of
c-Abl to the XbaI-XhoI fragments containing the selected 01, 02, 03,
05, 10, 17 or the control SK sequences. The duplex oligonucleotide
was incubated with (+) or without (3) 1 WM of GST-NX-HIS in
the presence of a 500-fold molar excess of poly(dI-dC)W(dI-dC). The
SK probe containing the pBSIISK plasmid sequence but lacking the
protein binding site was used as a control.
Fig. 5. DNase I footprinting of the GST-NX-HIS protein on the
XbaI-XhoI fragment of clone 05. The 73 bp DNA fragment was 3P
end-labelled at the XbaI site. The GST-NX-HIS fusion protein (lane
GNX) or BSA in the control (lane C) (10 WM each) was incubated
with the DNA for 15 min at 30‡C before digestion with 0.05 units
of DNase I. The products of the DNase I digestion were identi¢ed
by reference to the guanine markers (lane G). A portion of the
DNA sequence is indicated on the side of the gel. The sequence
protected from DNase I cleavage is bracketed and the sequence of
oligonucleotide 05 that binds to the protein is shown in bold letters.
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itate the phosphorylation of the C-terminal repeat domain of
RNA polymerase II.
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